FindTrial
Sign In

Estimating activity of the drug Peglyated Asparginase in children with Blood cancer (Acute Lymphoblastic Leukemia)

Plasma L-Asparginase Activity Assay (AAA) in children with Acute Lymphoblastic Leukemia/Lymphoma (ALL) after administration of Pegylated L-Asparginase: A prospective pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/036033
Enrollment
10
Registered
2021-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children less than 18 years with Acute Lymphoblastic Leukemia/Lymphoblastic Leukemia on curative intent and receiving Pegylated L Asparginase

Exclusion criteria

Exclusion criteria: Any child with Acute Lymphoblastic Leukemia and Downs Syndrome

Design outcomes

Primary

MeasureTime frame
1. To correlate the Asparginase activity with response post induction day 35 bone marrow and Minimal residual disease or chest X-ray Timepoint: At Day 7, 14 and 28 of Induction therapy of Acute Lymphoblastic Leukemia—

Secondary

MeasureTime frame
1. To correlate the asparginase activity with toxicity seen secondary to L-asparginase (Thrombosis, pancreatitis, hypersensitivity etcTimepoint: At Day 7, 14 and 28 of Induction therapy for Acute Lymphoblastic Leukemia—

Countries

India

Contacts

Public ContactVasudeva Bhat K

Kasturba Medical College

vasudev.bhat@manipal.edu9619114703

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 8, 2026